X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Methylnaltrexone bromide is the active ingredient in Relistor®, an FDA-approved prescription medication indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic pain.
Lead Product(s): Methylnaltrexone Bromide
Therapeutic Area: Gastroenterology Product Name: Relistor
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
Relistor (methylnaltrexone bromide) is an opioid antagonist, its subcutaneous formulation is being investigated in patients with resectable head and neck squamous cell carcinoma.
Lead Product(s): Methylnaltrexone Bromide
Therapeutic Area: Oncology Product Name: Relistor
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
RELISTOR (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
Lead Product(s): Methylnaltrexone Bromide
Therapeutic Area: Gastroenterology Product Name: Relistor
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
RELISTOR subcutaneous injection (methylnaltrexone bromide), an opioid antagonist indicated for treatment of opioid-induced constipation, The subgroup of patients in OIC-Rx cohort received RELISTOR had 0.7 fewer inpatient days per OIC ED encounter versus No-OIC-Rx cohort.
Lead Product(s): Methylnaltrexone Bromide
Therapeutic Area: Gastroenterology Product Name: Relistor
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
RELISTOR® (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
Lead Product(s): Methylnaltrexone Bromide
Therapeutic Area: Gastroenterology Product Name: Relistor
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
The three abstracts presented at PAINWeek represent the broad utilization of RELISTOR in the various settings of care in which OIC patients visit.
Lead Product(s): Methylnaltrexone Bromide
Therapeutic Area: Gastroenterology Product Name: Relistor
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2021
Details:
RELISTOR tablets & RELISTOR injection are indicated for the treatment of opioid-induced constipation in adults with chronic non-cancer pain, including patients with chronic pain related to cancer or its treatment who do not require frequent opioid dosage escalation.
Lead Product(s): Methylnaltrexone Bromide
Therapeutic Area: Gastroenterology Product Name: Relistor
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
